AR068102A1 - Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido - Google Patents

Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido

Info

Publication number: AR068102A1
Authority: AR; Argentina
Prior art keywords: pyrrolidin; pharmaceutical composition; carbonitrile; acetyl; dpp
Prior art date: 2007-08-16

Application number

ARP080103594A

Other languages

English (en)

Spanish (es)

Inventor

Klaus Dugi

Frank Himmelsbach

Michael Mark

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-16

Filing date

2008-08-15

Publication date

2009-11-04

2008-08-15 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2009-11-04 Publication of AR068102A1 publication Critical patent/AR068102A1/es

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 3
-1 phenyloxycarbonyl Chemical group 0.000 abstract 3
108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 2
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 2
239000003112 inhibitor Substances 0.000 abstract 2
QYRWMYNQCXSWLV-INIZCTEOSA-N (2s)-1-[2-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethylamino]acetyl]pyrrolidine-2-carbonitrile Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCNCC(=O)N1CCC[C@H]1C#N QYRWMYNQCXSWLV-INIZCTEOSA-N 0.000 abstract 1
JSYGLDMGERSRPC-FQUUOJAGSA-N (2s,4s)-4-fluoro-1-[2-[[(1r,3s)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@H]1C[C@@H](CN2N=CN=C2)CC1 JSYGLDMGERSRPC-FQUUOJAGSA-N 0.000 abstract 1
125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 abstract 1
URRAHSMDPCMOTH-LNLFQRSKSA-N Denagliptin Chemical compound C=1C=C(F)C=CC=1C([C@H](N)C(=O)N1[C@@H](C[C@H](F)C1)C#N)C1=CC=C(F)C=C1 URRAHSMDPCMOTH-LNLFQRSKSA-N 0.000 abstract 1
206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 abstract 1
229960001667 alogliptin Drugs 0.000 abstract 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 1
229950010300 denagliptin Drugs 0.000 abstract 1
201000001421 hyperglycemia Diseases 0.000 abstract 1
125000004551 isoquinolin-3-yl group Chemical group C1=NC(=CC2=CC=CC=C12)* 0.000 abstract 1
208000030159 metabolic disease Diseases 0.000 abstract 1
WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 abstract 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 abstract 1
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
125000006308 propyl amino group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 abstract 1
229960004937 saxagliptin Drugs 0.000 abstract 1
108010033693 saxagliptin Proteins 0.000 abstract 1
MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 abstract 1
229960004034 sitagliptin Drugs 0.000 abstract 1
IWYJYHUNXVAVAA-OAHLLOKOSA-N trelagliptin Chemical compound C=1C(F)=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 IWYJYHUNXVAVAA-OAHLLOKOSA-N 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 abstract 1
229960001254 vildagliptin Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Cardiology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Dermatology (AREA)
Biophysics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ARP080103594A 2007-08-16 2008-08-15 Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido AR068102A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP07114461		2007-08-16

Publications (1)

Publication Number	Publication Date
AR068102A1 true AR068102A1 (es)	2009-11-04

Family

ID=39870441

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP080103594A AR068102A1 (es)	2007-08-16	2008-08-15	Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido

Country Status (6)

Country	Link
AR (1)	AR068102A1 (fr)
CL (1)	CL2008002424A1 (fr)
PE (1)	PE20090987A1 (fr)
TW (1)	TW200918078A (fr)
UY (1)	UY31290A1 (fr)
WO (1)	WO2009022009A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1852108A1 (fr)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Compositions d'inhibiteurs de la DPP IV
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP2540725A1 (fr)	2006-05-04	2013-01-02	Boehringer Ingelheim International GmbH	Polymorphes de 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
JP5432720B2 (ja)	2007-03-13	2014-03-05	武田薬品工業株式会社	２−［［６−［（３ｒ）−３−アミノ−１−ピペリジニル］−３，４−ジヒドロ−３−メチル−２，４−ジオキソ−１（２ｈ）−ピリミジニル］メチル］−４−フルオロベンゾニトリルを含む固形製剤
CL2008002427A1 (es)	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
CL2008003653A1 (es) *	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) *	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh)	2008-12-23	2011-11-23	贝林格尔.英格海姆国际有限公司	有机化合物的盐形式
JP5685550B2 (ja)	2009-02-13	2015-03-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
KR20240090632A (ko)	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh)	2010-05-05	2013-02-27	贝林格尔.英格海姆国际有限公司	组合疗法
WO2011161161A1 (fr)	2010-06-24	2011-12-29	Boehringer Ingelheim International Gmbh	Thérapie du diabète
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AR085689A1 (es)	2011-03-07	2013-10-23	Boehringer Ingelheim Int	Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US8883800B2 (en)	2011-07-15	2014-11-11	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
JP6218811B2 (ja)	2012-05-14	2017-10-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (fr)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
EP3110449B1 (fr)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Utilisation médicale d'un inhibiteur de dpp-4
CN109310697A (zh)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	利格列汀和二甲双胍的组合

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6861440B2 (en) *	2001-10-26	2005-03-01	Hoffmann-La Roche Inc.	DPP IV inhibitors
CA2484306A1 (fr) *	2002-04-26	2003-11-06	Katsumi Maezono	Agent prophylactique et therapeutique du diabetes mellitus
WO2005000848A1 (fr) *	2003-06-20	2005-01-06	F. Hoffmann-La Roche Ag	Derives de pyrido[2,1-a]isoquinoline utilises comme inhibiteurs de dpp-iv
PL1753748T3 (pl) *	2004-05-12	2010-01-29	Pfizer Prod Inc	Pochodne proliny i ich zastosowanie jako inhibitorów peptydazy dipeptylowej IV
EP1799639B1 (fr) *	2004-10-12	2013-09-04	Glenmark Pharmaceuticals S.A.	Nouveaux inhibiteurs de dipeptidyle peptidase iv, compositions pharmaceutiques en contenant, et leur procédé de préparation
UY29694A1 (es) *	2005-07-28	2007-02-28	Boehringer Ingelheim Int	Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
MY147393A (en) *	2005-09-14	2012-11-30	Takeda Pharmaceutical	Administration of dipeptidyl peptidase inhibitors
PE20080251A1 (es) *	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
WO2007148185A2 (fr) *	2006-06-21	2007-12-27	Pfizer Products Inc.	3-amino-pyrrolidino-4-lactames substitués
CL2008000133A1 (es) *	2007-01-19	2008-05-23	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e

2008
- 2008-08-14 PE PE2008001380A patent/PE20090987A1/es not_active Application Discontinuation
- 2008-08-14 CL CL2008002424A patent/CL2008002424A1/es unknown
- 2008-08-14 UY UY31290A patent/UY31290A1/es not_active Application Discontinuation
- 2008-08-15 TW TW097131316A patent/TW200918078A/zh unknown
- 2008-08-15 AR ARP080103594A patent/AR068102A1/es unknown
- 2008-08-15 WO PCT/EP2008/060739 patent/WO2009022009A1/fr not_active Ceased

Also Published As

Publication number	Publication date
PE20090987A1 (es)	2009-08-14
CL2008002424A1 (es)	2009-09-11
TW200918078A (en)	2009-05-01
WO2009022009A1 (fr)	2009-02-19
UY31290A1 (es)	2009-03-31

Legal Events

Date	Code	Title	Description
2016-05-31	FB	Suspension of granting procedure

Publication	Publication Date	Title
AR068102A1 (es)	2009-11-04	Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido
AR071992A1 (es)	2010-07-28	Compuestos heterociclicos como inhibidores de dpp-4, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de nalfd.
AR072920A1 (es)	2010-09-29	Inhibidores de dpp-4 heterociclicos fusionados y su uso en el tratamiento para diabetes en pacientes inapropiados para terapia con metformina
ES2526648T3 (es)	2015-01-14	Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno
AR064969A1 (es)	2009-05-06	Composicion farmaceutica que comprende un derivado de pirazol -o- glucosido
Leuner et al.	2010	Improved mitochondrial function in brain aging and Alzheimer disease–the new mechanism of action of the old metabolic enhancer piracetam
CL2009000380A1 (es)	2010-09-21	Compuestos derivados de heterociclos, moduladores de beta-amiloide; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la enfermedad de alzheimer, angioplastia cerebral amiloide, demencia multiinfarto, sindrome de down, entre otras.
AR067970A1 (es)	2009-10-28	Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
NO20084853L (no)	2009-02-02	Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
US20110111014A1 (en)	2011-05-12	Methods and compositions for treatment of neurological disorders
EA201101187A1 (ru)	2012-10-30	Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
AR058620A1 (es)	2008-02-13	Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo
AR109605A2 (es)	2018-12-26	Método para tratar enfermedades vasculares periféricas, composición y utilización
AR047841A1 (es)	2006-03-01	Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
WO2008021196A3 (fr)	2008-11-06	Procédés et compositions de traitement de troubles médicaux
EA202091999A2 (ru)	2021-01-29	Применение ингибиторов dpp iv
NO20076357L (no)	2008-03-14	Azabicykliske heterocykler som cannabinoid reseptor modulatorer
BRPI0412909A (pt)	2006-09-26	uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer
CY1112281T1 (el)	2015-12-09	Αναστολεις διπεπτιδυλ πεπτιδασης για τη θεραπεια του διαβητη
CL2012000708A1 (es)	2012-09-07	Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades.
Sadowska-Bartosz et al.	2024	The cellular and organismal effects of nitroxides and nitroxide-containing nanoparticles
AR039164A1 (es)	2005-02-09	Sales de venlafaxina de baja solubilidad en agua
CL2011001178A1 (es)	2011-10-14	Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia.
AR065120A1 (es)	2009-05-20	Compuesto de aril pirazol azoespirodecanona, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende
BRPI0509245A (pt)	2007-09-11	cloridrato [4-(5-aminoetil-2-flúor-fenil)-piperidina-1-il](4-bromo-3 -metil-5-propóxi-tiofeno-2-il)-metanona como um inibidor de triptase de mastócito